TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Prevalence of burnout
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hemolysis Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Registered arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HIV PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total scores of Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to (PEG)IFN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Urological Association (AUA) Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD3 cell count post transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of life-threatening adverse reactions related to the gene therapy procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Change in reinnervation capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Mean Number of Micturition Episodes Per 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: SVR12: Plasma HCV RNA Level Less Than 25 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance of ASR and ReCap resurfacing implants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: NEURL1 gene expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RGS14 gene expression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Global Impression Scale of Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment Toxicity Related Mortality
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in VAS of temporomandibular pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Overall Knee Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change from Baseline in Overall Hip Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Newborns With a Birth Platelet Count > 50,000/uL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of lenalidomide and dexamethasone
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebral Bloodflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in sitting systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Physiological FDG uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Performance (logMAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone to implant contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: target value of SVV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Mean Oxygen Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of coronary artery lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Patients Tested and Treated
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Median survival of advanced pancreatic cancer patients
Endpoint domain: Mortality/survival
Primary endpoint: Rate of identification
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of test-meal consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linezolid resistance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Cognitive Fusion Questionnaire (CFQ13)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nocturnal Glycemic Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BPND
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antitumor effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Drug failure
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IIEF-EF score
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Platelet activity recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rate of complex partial seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Ten Meter Walk Test (10mWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Coronary Artery Area Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Anxiety levels measured by the Hamilton Anxiety Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving treatment target goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of households that order stoves and complete payments
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Spastic Paraplegia Rating Scale (SPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Post operative pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Visual Analog Skala Pain Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in the Richards - Campbell Sleep Scale
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in upper Gastrointestinal Symptom Severity Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Participation Strategies Self-Efficacy Scale (change)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Activity Card Sort (change)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient-Reported Outcomes Measurement Information System (PROMIS)- 29 (change)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Stroke Impact Scale (change)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Local relapse-free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Change from total exercise duration in exercise tolerance test (ETT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thirty day mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: disease exacerbation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration spent on ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28-ESR remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nocturnal Blood Pressure Dipping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Melatonin Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of patients who died
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Curve (AUC) from 0 to infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite HIV and HSV-2 infection rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Level of biochemical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose of Iodine-131 Anti B-1 Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Job Interview Skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Recidivism Self-Report
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants converted to <1% measured donor cf-DNA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who achieve 61% reduction in measured donor cf-DNA concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FeO2 at 3 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean sialorrhea related-disability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intra Ocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retinal Nerve Fiber Layer Thickness (RNFL) using OCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With First Case of SARS-CoV-2 RT-PCR-positive Symptomatic Illness
Endpoint domain: Adverse events/effects
Primary endpoint: AEs, SAEs, MAAEs, and AESIs Post Dose of IMP
Endpoint domain: Adverse events/effects
Primary endpoint: Cortical activity correlation with motor control tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Well being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Nocturnal cramps
Endpoint domain: Adverse events/effects
Primary endpoint: Change in CO2 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Oxygen Saturation Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of pleasantness ratings in the Ambiguous Scenarios Test for Depression-II
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total score of the Depression, Anxiety and Stress Scale-21 (DASS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total score on general, eudaimonic, hedonic, and social well-being as measured by the Pemberton Happiness Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resolution of Anterior Chamber Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Resolution of Ocular Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Transit time in the different GI regions until excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Difference in Resting pressure of the anorectal area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: fMRI changes in activation patterns of reward associated regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of variation in respiratory rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage of variation in heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cohen's kappa coefficient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Degree of flexion deformity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Sensitivity of blood MSI detected by NGS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of blood MSI detected by NGS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUCt)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevention of anastomosis leakage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: low-gamma neural oscillations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: linguistic performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: continuity of attention
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Percent Change From Baseline in Inflammatory, Noninflammatory and Total Lesion Count at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: changes in plasma concentrations of epinephrine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: changes in plasma concentrations of lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: changes in plasma concentrations of growth hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Grade 3-5 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Response to warm/cold temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion, ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed onset muscle soreness, DOMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance from chestwall to the heart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Distance from the heart to the mammary gland
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Temperament assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change Rate of prostate-specific antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Traumatic Stress Disorder symptoms severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Dry Mouth Symptom by Visual Analog Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Dry Mouth Symptoms by Xerostomia Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area under curve of doripenem serum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of complete plus partial responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Induction of a T-cell response after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ocular symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ophthalmologic tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first flatus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: first solid oral intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Modified Melasma Area and Severity index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Melanin index change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of clinical improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patterns of activation in cognitive control and emotion-related regions of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of etiological diagnoses in febrile travelers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Local injection site reactions (LISRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Liver fibrosis scores I-IV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of CCX168
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of Cmax (Tmax) of CCX168
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve (AUC) of CCX168 From Time 0 to Time t (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC of CCX168 From Time 0 to Infinity (AUC0-inf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients receiving transfusion of allogeneic red blood cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunohistochemical expression of hormonal receptors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of females that got pregnant
Endpoint domain: Mortality/survival
Primary endpoint: Percentage excess weight loss after bariatric surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of death, stroke, and MI
Endpoint domain: Mortality/survival
Primary endpoint: Total Body Bone Mineral Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in maximal voluntary isometric contraction of quadriceps muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Repositioning success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of primary cesarean section (CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 6 Minute walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Constant cardiopulmonary exercise testing change in endurance time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants who use preventive prophylaxis (PrEP)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who use non-occupational post-exposure prophylaxis (nPEP)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants who take the HIV and Sexually Transmitted Infection (STI) tests
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Frequency of zoster antecedent
Endpoint domain: Adverse events/effects
Primary endpoint: VO2 (oxygen consumption)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants entered into the database
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum Tolerated Dose (MTD) of clofarabine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reproducibility of Anticholinergic side effects Questionnaire (AQUA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of AQUA
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Comprehension of AQUA
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: B17MP AUC0-t
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Psychiatric Diagnosis
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Stress Reactivity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in walking symmetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Platelet Aggregability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variation in the performance of Six Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in the performance of Muscle strength Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of circulating tumor cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Any stroke or death related to the procedure within 180 days
Endpoint domain: Mortality/survival
Primary endpoint: Complete obliteration of target aneurysm and patency of target vessel (less than 50% stenosis) confirmed by angiography at 180 days after the procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of volume of perihematomal edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Grades II-IV Acute GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Circuit activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average time to plan surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Remaining adhesive area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle lipid content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients in defined disease severity categories
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement level of patients' individual satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Generalized Anxiety Disorder Scale (GAD-7)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing